NCT04505631 (SISCOVID) is a clinical trial in Covid19, sponsored by Groupe Hospitalier de la Region de Mulhouse et Sud Alsace.

Who is sponsoring NCT04505631?

NCT04505631 is sponsored by Groupe Hospitalier de la Region de Mulhouse et Sud Alsace.

What condition does NCT04505631 study?

NCT04505631 studies Covid19, Dyspnea.

Is NCT04505631 still recruiting?

NCT04505631 is currently completed. Last updated 17 November 2025.

Last reviewed 2025-11-17 · How we verify

NCT04505631: SISCOVID

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Follow-up of Respiratory Sequelae of Hospitalized Patients With COVID-19

Completed Last updated 17 November 2025

What this trial tests

trial in Covid19 in 332 participants. Completed in 15 January 2021.

Timeline

10 June 2020

Primary endpoint
15 January 2021

15 January 2021

Quick facts

Lead sponsor	Groupe Hospitalier de la Region de Mulhouse et Sud Alsace
Status	Completed
Study type	OBSERVATIONAL
Enrollment	332
Start date	10 June 2020
Primary completion	15 January 2021
Estimated completion	15 January 2021
Sites	14 locations across France

Conditions studied

Covid19 — all drugs for Covid19 →
Dyspnea — all drugs for Dyspnea →

Sponsor

Groupe Hospitalier de la Region de Mulhouse et Sud Alsace

Who can join

18 and older, any sex, with Covid19 or Dyspnea. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this multicenter observational study is to describe respiratory sequelae of COVID-19 patients hospitalized for severe pneumonia requiring oxygen supply.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Covid-19 sequelae in working age patients: A systematic review.
d'Ettorre G, Gentilini Cacciola E, Santinelli L, De Girolamo G, et al · · 2022 · cited 29× · PMID 34655247 · DOI 10.1002/jmv.27399
Mid-term pulmonary sequelae after hospitalisation for COVID-19: The French SISCOVID cohort.
Calcaianu G, Degoul S, Michau B, Payen T, et al · · 2022 · cited 6× · PMID 35905553 · DOI 10.1016/j.resmer.2022.100933

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other Groupe Hospitalier de la Region de Mulhouse et Sud Alsace trials

Trials by the same sponsor.

NCT07344350 — A Non-randomised, Non-inferiority Comparative Study of Oral Actiskenan (Morphine Sulfate) Versus Intranasal Sufentanil i · not yet recruiting
NCT07250217 — Determination of Epigenetic Markers of Acute Myeloblastic Leukemia in Elderly Patients · NA · recruiting
NCT06399094 — Frequency-time Analysis of Pathological Lung Sounds: Detection and Quantification of Pathological Sounds in Patients Wit · terminated
NCT06460441 — Comparison of the SUNRISE© Device With Ventilatory Polygraphy for the Diagnosis of Obstructive Sleep Apnea Hypopnea Synd · completed
NCT05835908 — Follow-up of Patients Referred to Unscheduled Care Centers by the Emergency Call Center in the Haut-Rhin Department, Fra · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04505631 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Groupe Hospitalier de la Region de Mulhouse et Sud Alsace
Last refreshed: 17 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04505631.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing